Private Prescription: Skip the NHS Queue for Weight Management
What the Difference Between Mounjaro and Wegovy Means for Private Patients
The key difference between mounjaro and wegovy lies in their mechanisms of action, which directly impacts availability through private prescription routes. Wegovy (semaglutide) is a GLP-1 receptor agonist manufactured by Novo Nordisk, whilst Mounjaro (tirzepatide) from Eli Lilly targets both GIP and GLP-1 receptors as a dual agonist. For private patients, Wegovy offers superior storage flexibility with 6 weeks room temperature tolerance compared to Mounjaro's 21-day limit. This practical advantage matters significantly when travelling or managing your treatment independently without frequent pharmacy visits.
Private prescription access eliminates the NHS bottleneck where patients face GP referrals followed by specialist weight management service waiting lists exceeding 6 months. EverydayMeds provides direct access to genuine Novo Nordisk Wegovy through our GPhC-registered pharmacy #9012878, with clinical assessments completed within 24 hours. Both medications are prescription-only medicines requiring clinical oversight, but private routes offer the same pharmaceutical-grade treatments without healthcare system delays.
Understanding Price Differences Between Mounjaro and Wegovy Private Prescriptions
When comparing what the difference between mounjaro and wegovy costs privately, Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose with code FIRST40 applied at checkout. The dose escalation follows: £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), £139.99 for 1.7mg (weeks 13-16), and £209.99 for 2.4mg maintenance dosing. Our bundle options like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing convenient multi-month supply. Returning customers benefit from code DOSE25 for ongoing treatment affordability.
Private prescription costs reflect the pharmaceutical-grade quality and cold-chain logistics required for both treatments. Wegovy's established market presence and Novo Nordisk's manufacturing scale contribute to competitive pricing structures. The investment in private treatment eliminates opportunity costs associated with NHS waiting periods, allowing patients to begin clinically-supervised weight management immediately rather than delaying for months whilst eligibility criteria are assessed through traditional healthcare pathways.
Clinical Evidence: What the Difference Between Mounjaro and Wegovy Shows in Trials
In clinical trials, patients taking Wegovy alongside diet and exercise demonstrated significant weight management outcomes in the STEP programme. STEP 1 showed approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, whilst STEP 5 sustained 15.2% weight reduction at 2 years. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events (HR 0.80), as documented by Wilding et al., NEJM, 2021.
Mounjaro's SURMOUNT trials showed different outcomes due to its dual GIP/GLP-1 mechanism, but direct comparison between trial data isn't appropriate given different study designs, populations, and endpoints. Both medications work through hormone pathway modulation but target different receptor combinations. Your prescriber can help determine which mechanism may be more suitable based on your individual clinical profile and treatment goals during assessment.
How Wegovy Differs from Mounjaro in Weight Management Mechanisms
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that signals satiety to brain appetite centres. This mechanism reduces appetite between meals and promotes feelings of fullness after smaller portions, supporting adherence to reduced-calorie dietary approaches. The once-weekly FlexTouch pen delivery maintains consistent semaglutide levels, working continuously to modulate hunger signals and food cravings. Unlike dual-pathway treatments, Wegovy's focused GLP-1 action has extensive clinical validation across multiple patient populations. The treatment requires commitment to lifestyle modifications including increased physical activity, as the medication supports rather than replaces behavioural interventions for sustainable weight management outcomes.
Private Prescription Process: What the Difference Between Mounjaro and Wegovy Ordering Means
EverydayMeds streamlines access to Wegovy through our 3-minute online clinical assessment, eliminating GP referral requirements that traditionally precede specialist consultations. Our prescriber review occurs within standard 3 working days or express 24-hour service, followed by next-day delivery using temperature-controlled logistics to maintain pharmaceutical integrity. The process bypasses NHS eligibility criteria assessments and waiting list placement, providing direct access to the same Novo Nordisk Wegovy available through traditional healthcare routes. Payment processing includes automatic application of discount codes FIRST40 for new patients or DOSE25 for continuing treatment. Cold-chain delivery ensures your prescription-only medicine arrives in optimal condition for immediate use according to prescribed dosing schedules.
Storage and Practical Differences Between Mounjaro and Wegovy Prescriptions
Storage requirements highlight a practical difference between mounjaro and wegovy that impacts private prescription convenience. Wegovy maintains effectiveness for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This advantage proves significant for travel, work schedules, or lifestyle flexibility where refrigeration access varies. Both require 2-8°C refrigerated storage before first use, but Wegovy's extended ambient stability reduces logistical concerns for busy patients. The FlexTouch pen design provides consistent dose delivery throughout the escalation schedule from 0.25mg through 2.4mg maintenance dosing. Proper storage maintains pharmaceutical potency essential for therapeutic outcomes alongside dietary and exercise commitments.
Why Private Patients Choose Wegovy Over NHS Routes for Weight Management
Private prescription eliminates the sequential barriers inherent in NHS weight management pathways: GP consultation, referral justification, specialist service placement, and extended waiting periods often exceeding 6 months. EverydayMeds patients access the same genuine pharmaceutical products immediately, beginning treatment whilst NHS patients remain in assessment queues. The financial investment reflects priority access to clinically-proven weight management support without healthcare system bottlenecks.
Private treatment offers scheduling flexibility, direct prescriber communication, and personalised monitoring arrangements that institutional healthcare struggles to provide. Patients maintain treatment continuity without service interruptions, appointment rescheduling, or administrative delays that can disrupt therapeutic momentum. The cost-per-outcome calculation often favours private routes when considering the time value of delayed treatment and sustained motivation factors crucial for long-term weight management success.
Getting Started: What the Difference Between Mounjaro and Wegovy Means for Your Treatment Journey
Beginning with Wegovy through EverydayMeds means accessing established dose escalation protocols proven in extensive clinical research programmes. The 0.25mg starter dose costs £79.99 with code FIRST40, progressing systematically through validated increases that optimise therapeutic response whilst managing potential side effects. Our clinical team provides ongoing support throughout your treatment journey, ensuring appropriate monitoring and dose adjustments when clinically indicated. Both Wegovy and Mounjaro are available from EverydayMeds - your prescriber can help determine which is right for you based on individual clinical factors, lifestyle requirements, and treatment preferences. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, with next-day delivery available once your prescription is approved by our qualified healthcare professionals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
